Drug discovery is one of the most expensive failures in modern science. A drug that works in mice fails in humans 90% of the time. The industry spends a decade and a billion dollars finding out. And yet, for fifty years, we kept doing the same thing — because there was no better model of "human" to test against.
CellType thinks that era is over.
The two-person YC W2026 company from New Haven and New York has built what they call "the agentic drug company" — a platform where AI agents run the full drug discovery pipeline on top of biological foundation models that simulate human biology at the cellular level. Instead of mice, they simulate patients. Instead of wet-lab trial-and-error, they run computational screens across thousands of drug candidates in days.
The kicker: they've already validated it. A model prediction about cancer immunotherapy — identifying a compound that could make "cold tumors" visible to the immune system — was subsequently confirmed in living cells, increasing antigen presentation by roughly 50%. That's not a demo. That's a result.
What They Do
CellType's product is a B2B platform for pharmaceutical companies. Pharma brings their drug candidates, disease areas, and biological questions. CellType runs AI-driven discovery workflows to prioritize which molecules are worth taking into expensive wet-lab experiments or clinical trials.
The target customer is a Top 10 pharma company that spends north of $1B per approved drug and has a preclinical attrition rate that keeps their CFO awake. According to the founders, all current pharma deals came inbound — a strong signal they've hit something real.
Revenue is almost certainly service-based for now: pharma companies pay for discovery runs, hypothesis validation, and platform access. The long-term play is more interesting — if you are the virtual human that all pharma companies query before they run a single animal study, you're upstream of every drug on the planet.
They've signed a strategic MOU with Senhwa Biosciences (March 2026) to integrate their AI platform into the clinical development of CX-4945 (Silmitasertib), a lead cancer compound. That's not a tech partnership — that's a drug company betting their lead asset on CellType's predictions.
